Pfizer Vaccine Shows 100% Efficacy in Adolescents, Says Company
Results of phase 3 trials by Pfizer shows the vaccine is safe and effective in kids between the ages of 12 and 15.
Pfizer on Wednesday, 31 March, announced that the COVID vaccine it has developed along with BioNTech is safe and shows ‘robust antibody responses’ in adolescence.
According to the statement jointly released by the two companies, the phase 3 trials conducted on participants aged 12-15 years old, “demonstrated 100% efficacy and robust antibody responses.”
It also says that the results in this age bracket exceed that of the trial conducted on participants between the ages of 16 and 25 years, in an earlier analysis.
“We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.”Albert Bourla, Chairman and Chief Executive Officer, Pfizer
The companies plan to submit these findings to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) at the earliest.
Albert Bourla, Chairman and Chief Executive Officer, Pfizer, says they would like to do so with the hopes that vaccination of this age group could begin before the next school year begins.
Speaking of the urgency to vaccinate children under the age of 18, Ugur Sahin, CEO and Co-founder of BioNTech said, “It is very important to enable them to get back to everyday school life and to meet friends and family while protecting them and their loved ones.”
“The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant.”Ugur Sahin, CEO and Co-founder of BioNTech
About the Trial Data
The phase 3 clinical trial was conducted by Pfizer-BioNtech on 2,260 adolescents 12 to 15 years of age in the United States.
“Vaccination with BNT162b2 elicited SARS-CoV-2–neutralizing antibody geometric mean titers (GMTs) of 1,239.5, demonstrated a strong immunogenicity in a subset of adolescents one month after the second dose,” says the statement.
As of last week, Pfizer has also started conducting phases 1, 2, and 3 trials on even younger children between the ages of 11 years and 6 months ‘to further evaluate the safety, tolerability, and immunogenicity in them.
(Subscribe to FIT on Telegram)
Subscribe To Our Daily Newsletter Now.